SCHEMBL6478170

SCHEMBL6478170

COc1cc2c(=O)n(COC(=O)C(C)(C)C)cnc2cc1OCCCn1ccnn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNF P01375 3/20 0.48
HDAC6 Q9UBN7 3/20 0.48
PDGFRB P09619 5/20 0.43
SRC P12931 1/20 0.42
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC9 Q9UKV0 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41
FGFR1 P11362 4/20 0.40
FLT1 P17948 4/20 0.40
FGFR2 P21802 4/20 0.40
FGFR4 P22455 4/20 0.40
FGFR3 P22607 4/20 0.40
FLT4 P35916 4/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5499250 0.96 HDAC6 (0.49) TNFHDAC6PDGFRBSRCHDAC3
SCHEMBL5562061 0.85 HDAC6 (0.55) TNFHDAC6HDAC3HDAC4HDAC1
SCHEMBL2922474 0.84 TNF (0.54) TNFHDAC6HDAC3HDAC4HDAC1
SCHEMBL664005 0.83 HDAC6 (0.55) TNFHDAC6HDAC3HDAC4HDAC1
SCHEMBL4386072 0.83 TNF (0.49) TNFHDAC6SRCKDREGFR
SCHEMBL4380672 0.83 HDAC6 (0.49) TNFHDAC6PDGFRBHDAC3HDAC4
SCHEMBL2947219 0.83 EHMT2 (0.50) TNFHDAC6KDREHMT2EHMT1
SCHEMBL4381827 0.82 HDAC6 (0.51) TNFHDAC6HDAC3HDAC4HDAC1
SCHEMBL6789011 0.82 TNF (0.48) TNFHDAC6SRCKDREGFR
SCHEMBL7210734 0.82 HDAC6 (0.53) TNFHDAC6HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6939866-B2 Quinazoline derivatives ASTRAZENECA AB (SE) 2005-09-06 US disclosed
US-20040044015-A1 Quinazoline derivatives ASTRAZENECA AB (SE) 2004-03-04 US disclosed
EP-1326860-A1 QUINAZOLINE DERIVATIVES AstraZeneca AB (SE) 2003-07-16 EP disclosed
WO-2002030926-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2002-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044015-A1 Quinazoline derivatives NQO2, NRAS, TOP1 TNF 1747/4885HDAC6 1075/4885PDGFRB 2921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.